A New Editor-in-Chief Invites Submissions
AAPS’ flagship fully open access journal, AAPS Open, published with Springer Nature, is now accepting submissions under the new leadership of Editor-in-Chief Andrea Allmendinger, Ph.D.
Allmendinger has been in the Pharmaceutical Development Department of Roche/Genentech in Basel since 2013, where she has been responsible for formulation and process development for clinical phase 1-3 projects and commercial transfer activities for both large molecules and recently also for synthetic drugs. She is also a lecturer at the University of Freiburg, Germany, in the department of Pharmaceutical Technology and Biopharmacy, and she is currently building her own research group. Allmendinger studied Pharmacy at the University of Heidelberg, Germany, and the University College London. She obtained her doctorate in Pharmaceutical Technology from the University of Basel, Switzerland.
Allmendinger is enthusiastic about driving innovative projects across functional disciplines and is a regularly invited speaker. At international conferences. She has an extensive record of peer-reviewed research articles, communications, perspectives, and book chapters, and she previously served on the Pharmaceutical Research editorial advisory board under Editor-in-Chief Tonglei Li, Ph.D.
Some of her recently published articles include:
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products, Pharmaceutical Research
Excipients for Room Temperature Stable Freeze-Dried Monoclonal Antibody Formulations, Journal of Pharmaceutical Sciences
Glass Leachables as a Nucleation Factor for Free Fatty Acid Particle Formation in Biopharmaceutical Formulations, Journal of Pharmaceutical Sciences
AAPS Open provides a global forum for the rapid publication of original research and discussion that demonstrates applications of scientific concepts and techniques across the breadth of the pharmaceutical sciences.
All content published in AAPS Open is peer reviewed. The journal welcomes reports from experimental or theoretical studies during the entire course of drug candidate development, for both synthetic drugs as well as biopharmaceutical products including vaccines, cell and gene therapeutics, and other new modalities such as nucleotide-based therapeutics.
As a fully open access journal, authors of published articles retain copyright and are free to reproduce and disseminate their work. Open access articles are also freely available to anyone worldwide—no subscription or access fee is required to read the articles. However, to support these practices, authors of accepted articles must pay an article processing fee of $1,570.
Learn More
View the complete scope, benefits of open access publishing, and submit your work!